Compare Stocks: AKBA, OPK, ENTA, and DERM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.98 +4.4%	$1.04	$0.81 ▼ $3.20	$260.06M	0.19	8.67 million shs	5.09 million shs
DERM Journey Medical	$7.25 +3.7%	$7.05	$4.31 ▼ $9.56	$197.29M	1.09	134,080 shs	227,372 shs
ENTA Enanta Pharmaceuticals	$12.42 +2.6%	$13.24	$7.05 ▼ $17.15	$352.71M	0.93	246,835 shs	164,644 shs
OPK OPKO Health	$1.73 +2.4%	$1.44	$0.98 ▼ $1.75	$1.26B	1.5	2.90 million shs	3.48 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+2.49%	-2.53%	+3.52%	-14.68%	-66.72%
DERM Journey Medical	-4.38%	-5.28%	-9.81%	+4.33%	-4.31%
ENTA Enanta Pharmaceuticals	-0.74%	-7.70%	-10.10%	-13.87%	+58.51%
OPK OPKO Health	+1.20%	+8.33%	+14.19%	+15.75%	+16.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.98 +4.4%	$1.04	$0.81 ▼ $3.20	$260.06M	0.19	8.67 million shs	5.09 million shs
DERM Journey Medical	$7.25 +3.7%	$7.05	$4.31 ▼ $9.56	$197.29M	1.09	134,080 shs	227,372 shs
ENTA Enanta Pharmaceuticals	$12.42 +2.6%	$13.24	$7.05 ▼ $17.15	$352.71M	0.93	246,835 shs	164,644 shs
OPK OPKO Health	$1.73 +2.4%	$1.44	$0.98 ▼ $1.75	$1.26B	1.5	2.90 million shs	3.48 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+2.49%	-2.53%	+3.52%	-14.68%	-66.72%
DERM Journey Medical	-4.38%	-5.28%	-9.81%	+4.33%	-4.31%
ENTA Enanta Pharmaceuticals	-0.74%	-7.70%	-10.10%	-13.87%	+58.51%
OPK OPKO Health	+1.20%	+8.33%	+14.19%	+15.75%	+16.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.43	Hold	$3.90	297.96% Upside
DERM Journey Medical	2.25	Hold	$14.00	93.10% Upside
ENTA Enanta Pharmaceuticals	2.67	Moderate Buy	$21.00	69.08% Upside
OPK OPKO Health	2.00	Hold	$1.55	-10.40% Downside

Current Analyst Ratings Breakdown

Latest AKBA, OPK, ENTA, and DERM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/15/2026	AKBA Akebia Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
9/8/2026	AKBA Akebia Therapeutics	Westpark Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.50
8/31/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	OPK OPKO Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/13/2026	DERM Journey Medical	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00 ➝ $15.00
8/7/2026	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$1.00
8/6/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	OPK OPKO Health	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$236.20M	1.15	N/A	N/A	$0.12 per share	8.17
DERM Journey Medical	$61.86M	3.31	N/A	N/A	$0.96 per share	7.55
ENTA Enanta Pharmaceuticals	$65.32M	5.54	N/A	N/A	$3.03 per share	4.10
OPK OPKO Health	$606.90M	2.13	N/A	N/A	$1.67 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	11/9/2026 (Estimated)
DERM Journey Medical	-$11.43M	-$0.22	N/A	8.06	N/A	-8.95%	-20.23%	-6.60%	11/11/2026 (Estimated)
ENTA Enanta Pharmaceuticals	-$81.89M	-$2.41	N/A	N/A	N/A	-96.89%	-61.84%	-20.70%	11/16/2026 (Estimated)
OPK OPKO Health	-$225.68M	-$0.09	N/A	N/A	N/A	-12.40%	-5.88%	-3.83%	11/4/2026 (Estimated)

Latest AKBA, OPK, ENTA, and DERM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	DERM Journey Medical	-$0.0225	-$0.01	+$0.0125	-$0.01	$18.36 million	$18.51 million
8/10/2026	Q3 2026	ENTA Enanta Pharmaceuticals	-$0.5095	-$0.67	-$0.1605	-$0.67	$16.76 million	$14.36 million
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million
7/27/2026	Q2 2026	OPK OPKO Health	-$0.08	-$0.01	+$0.07	-$0.01	$131.23 million	$163.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPK OPKO Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
DERM Journey Medical	0.64	1.59	1.41
ENTA Enanta Pharmaceuticals	N/A	3.76	3.76
OPK OPKO Health	0.28	3.35	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
DERM Journey Medical	7.25%
ENTA Enanta Pharmaceuticals	94.99%
OPK OPKO Health	64.63%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
DERM Journey Medical	14.53%
ENTA Enanta Pharmaceuticals	11.48%
OPK OPKO Health	44.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	194	277.11 million	265.19 million	Optionable
DERM Journey Medical	58	28.22 million	24.12 million	N/A
ENTA Enanta Pharmaceuticals	120	29.12 million	25.78 million	Optionable
OPK OPKO Health	1,373	746.33 million	412.57 million	Optionable

AKBA, OPK, ENTA, and DERM Headlines

Recent News About These Companies

OPKO Health (NASDAQ:OPK) Reaches New 12-Month High - Should You Buy?

September 22 at 11:59 AM | marketbeat.com

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

September 21 at 1:36 PM | finance.yahoo.com

OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?

September 21 at 10:35 AM | zacks.com

OPKO Health stock gains support from improved Q2 2026 results

September 19 at 7:14 AM | ad-hoc-news.deA

OPKO Health (NASDAQ:OPK) Shares Pass Above 50-Day Moving Average - Should You Sell?

September 19 at 2:59 AM | marketbeat.com

The Bull Case For OPKO Health (OPK) Could Change Following New Mazdutide Royalty-Backed Financing Strategy

September 15, 2026 | finance.yahoo.com

OPKO Health (OPK) Cashes In A Future Royalty Stream Early

September 13, 2026 | finance.yahoo.com

OPKO Health (OPK) Cashes In A Future Royalty Stream Early

September 13, 2026 | insidermonkey.com

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months

September 11, 2026 | marketbeat.com

OPKO Health op Wells Fargo-conferentie: cashrijke verschuiving naar therapeutica

September 10, 2026 | nl.investing.com

OPKO Health, Inc. (OPK)

September 9, 2026 | finance.yahoo.com

Bank of New York Mellon Corp Takes Position in OPKO Health, Inc. $OPK

September 9, 2026 | marketbeat.com

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 8, 2026 | finance.yahoo.com

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 8, 2026 | globenewswire.com

OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of "Hold" by Brokerages

September 8, 2026 | marketbeat.com

Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?

September 4, 2026 | finance.yahoo.com

Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?

September 3, 2026 | finance.yahoo.com

OPKO Health (NASDAQ:OPK) Sets New 1-Year High - Here's Why

September 3, 2026 | marketbeat.com

OPKO Health (NASDAQ:OPK) Trading Up 8.2% - Here's Why

September 2, 2026 | marketbeat.com

BlackRock Inc. Takes Position in OPKO Health, Inc. $OPK

September 1, 2026 | marketbeat.com

Cocrystal Pharma: The Strategic Reset Investors May Be Missing

August 31, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AKBA, OPK, ENTA, and DERM Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.98 +0.04 (+4.42%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 +0.00 (+0.20%)

As of 07:59 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Journey Medical NASDAQ:DERM

$7.25 +0.26 (+3.72%)

Closing price 04:00 PM Eastern

Extended Trading

$7.24 0.00 (-0.07%)

As of 07:30 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Enanta Pharmaceuticals NASDAQ:ENTA

$12.42 +0.31 (+2.56%)

Closing price 04:00 PM Eastern

Extended Trading

$12.42 -0.01 (-0.04%)

As of 07:30 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

OPKO Health NASDAQ:OPK

$1.73 +0.04 (+2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.71 -0.02 (-1.04%)

As of 07:56 PM Eastern

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, OPK, ENTA, and DERM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, OPK, ENTA, and DERM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, OPK, ENTA, and DERM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AKBA, OPK, ENTA, and DERM Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Journey Medical NASDAQ:DERM

Enanta Pharmaceuticals NASDAQ:ENTA

OPKO Health NASDAQ:OPK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, OPK, ENTA, and DERM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, OPK, ENTA, and DERM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, OPK, ENTA, and DERM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AKBA, OPK, ENTA, and DERM Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Journey Medical NASDAQ:DERM

Enanta Pharmaceuticals NASDAQ:ENTA

OPKO Health NASDAQ:OPK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools